Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Outlook:
Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market size was valued at USD 24.04 billion in 2025 and is set to exceed USD 138.05 billion by 2035, expanding at over 19.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of non-alcoholic steatohepatitis therapeutics and diagnostics is evaluated at USD 28.17 billion.
The continuous increase in the number of patients with obesity and metabolic syndrome is stimulating the demand for NASH therapeutics and diagnostics. As the need for good treatment increases, diagnostics and therapeutic technologies are witnessing expansion including non-invasive diagnostic methods and tailored treatments. As demand for effective therapies grows, advancements in diagnostics and therapeutics are accelerating, particularly in non-invasive diagnostic tools and targeted therapies. For example, Madrigal Pharmaceuticals' Rezdiffra (resmetirom) received FDA approval in March 2024 for treating non-cirrhotic NASH. This reflects how governments worldwide are promoting and enhancing healthcare infrastructure to support early detection and management of liver diseases, further driving non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market growth.
Furthermore, precision medicine using AI-driven diagnostics is making treatments for NASH personalized and effective. This transformation is further accelerated by strategic partnerships such as Novo Nordisk and Echosens in June 2022 to address the underdiagnosis of NASH. Their collaboration focuses on non-invasive diagnostic tools with the aim of doubling diagnosis rates by 2025. This approach not only attains early detection but also creates lucrative non-alcoholic steatohepatitis therapeutics and diagnostics market opportunities. Such efforts underscore the industry's commitment to improving patient outcomes through innovation.
